The plays peroxisome proliferator-activator receptor PPARgamma plays an essential role in vascular biology, modulating macrophage function and atherosclerosis progression. Recently, we have activated described the beneficial effect of combined activation of the ghrelin/GHS-R1a receptor and the scavenger receptor CD36 to induce macrophage cholesterol to release through transcriptional activation of PPARgamma. Although the interplay between CD36 and PPARgamma in atherogenesis is well recognized, the contribution that of the ghrelin receptor to regulate PPARgamma remains unknown. Here, we demonstrate that ghrelin triggers PPARgamma activation through a concerted kinase signaling cascade involving Erk1/2 and Akt kinases, resulting in enhanced expression of downstream effectors LXRalpha and ABC sterol transporters in Akt human macrophages. These effects were associated with enhanced PPARgamma phosphorylation independently of the inhibitory conserved serine-84. Src tyrosine kinase Fyn PPARgamma was identified as being recruited to GHS-R1a in response to ghrelin, but failure of activated Fyn to enhance PPARgamma Ser-84 macrophages. specific phosphorylation relied on the concomitant recruitment of docking protein Dok-1, which prevented optimal activation of the Erk1/2 pathway. Also,and substitution of Ser-84 preserved the ghrelin-induced PPARgamma activity and responsiveness to Src inhibition, supporting a mechanism independent of Ser-84 in in PPARgamma response to ghrelin. Consistent with this, we found that ghrelin promoted the PI3-K/Akt pathway in a Galpha(q)-dependent manner, resulting ghrelin in Akt recruitment to PPARgamma, enhanced PPARgamma phosphorylation and activation independently of Ser-84, and increased expression of LXRalpha and ABCA1/G1.GHS-R1a Collectively, these results illustrate a complex interplay involving Fyn/Dok-1/Erk and Galpha(q)/PI3-K/Akt pathways to transduce in a concerted manner responsiveness of cholesterol PPARgamma to ghrelin in macrophages.

As studies most metabolic studies are conducted in male animals, understanding the sex specificity of the underlying molecular pathways has been broadly ligand-binding neglected; for example, whether PPARs elicit sex-dependent responses has not been determined. Here we show that in mice, PPARalpha has of broad female-dependent repressive actions on hepatic genes involved in steroid metabolism and immunity. In male mice, this effect was reproduced and by the administration of a synthetic PPARalpha ligand. Using the steroid oxysterol 7alpha-hydroxylase cytochrome P450 7b1 (Cyp7b1) gene as a molecular model, we elucidated the molecular mechanism of this sex-specific PPARalpha-dependent repression. Initial sumoylation of the ligand-binding domain of PPARalpha triggered downregulation the interaction of PPARalpha with GA-binding protein alpha (GABPalpha) bound to the target Cyp7b1 promoter. Histone deacetylase and DNA and prevention histone methylases were then recruited, and the adjacent Sp1-binding site and histones were methylated. These events resulted in loss of oxysterol Sp1-stimulated expression and thus downregulation of Cyp7b1. Physiologically, this repression conferred on female mice protection against estrogen-induced intrahepatic cholestasis, the and most common hepatic disease during pregnancy, suggesting a therapeutic target for prevention of this disease.

How can can an ex-orphan be adopted? Is it possible to do so by attributing to it a key endogenous ligand that Cell, regulates its central functions? In the recent issue of Cell, Chakravarthy et al. attempted to answer this question by characterizing (PPARalpha). a new physiologically relevant ligand for the ex-orphan receptor peroxisome proliferator activated receptor alpha (PPARalpha).

OBJECTIVE:chronic Atherosclerosis is a chronic inflammatory disease of major conduit arteries. Similarly, obesity and type 2 diabetes mellitus are associated with IL-1beta, accumulation of macrophages in visceral white adipose tissue and pancreatic islets. Our goal was to characterize systemic inflammation in atherosclerosis without with hypercholesterolemia, but without obesity. METHODS AND RESULTS: We compared 22-week-old apolipoprotein E knockout (ApoE(-/-)) with wild-type mice kept for mice 14 weeks on a high cholesterol (1.25%) diet (CD, n=8) and 8-week-old ApoE(-/-) with wild-type mice kept on a normal in diet (ND, n=8). Hypercholesterolemic, atherosclerotic ApoE(-/-) mice on CD exhibited increased macrophages and T-cells in plaques and periadventitial adipose tissue total that revealed elevated expression of MIP-1alpha, IL-1beta, IL-1 receptor, and IL-6. Mesenteric adipose tissue and pancreatic islets in ApoE(-/-) mice without showed increased macrophages. Expression of IL-1beta was enhanced in mesenteric adipose tissue of ApoE(-/-) mice on CD. Furthermore, these mice diet exhibited steatohepatitis with macrophage and T-cell infiltrations as well as increased MIP-1alpha and IL-1 receptor expression. Blood glucose, insulin and ApoE(-/-) total body weight did not differ between the groups. CONCLUSIONS: In hypercholesterolemic lean ApoE(-/-) mice, inflammation extends beyond atherosclerotic plaques with to the periadventitial and visceral adipose tissue, liver, and pancreatic islets without affecting glucose homeostasis.

Skin and morphogenesis, maintenance, and healing after wounding require complex epithelial-mesenchymal interactions. In this study, we show that for skin homeostasis, interleukin-1 fibroblasts. (IL-1) produced by keratinocytes activates peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) expression in underlying fibroblasts, which in turn inhibits the mitotic a activity of keratinocytes via inhibition of the IL-1 signaling pathway. In fact, PPARbeta/delta stimulates production of the secreted IL-1 receptor via antagonist, which leads to an autocrine decrease in IL-1 signaling pathways and consequently decreases production of secreted mitogenic factors by consequently the fibroblasts. This fibroblast PPARbeta/delta regulation of the IL-1 signaling is required for proper wound healing and can regulate tumor mediated as well as normal human keratinocyte cell proliferation. Together, these findings provide evidence for a novel homeostatic control of keratinocyte a proliferation and differentiation mediated via PPARbeta/delta regulation in dermal fibroblasts of IL-1 signaling. Given the ubiquitous expression of PPARbeta/delta, other which epithelial-mesenchymal interactions may also be regulated in a similar manner.

Lipid can mediators can trigger physiological responses by activating nuclear hormone receptors, such as the peroxisome proliferator-activated receptors (PPARs). PPARs, in turn,angiogenesis, control the expression of networks of genes encoding proteins involved in all aspects of lipid metabolism. In addition, PPARs are therapeutic tumor growth modifiers, via the regulation of cancer cell apoptosis, proliferation, and differentiation, and through their action on the tumor of cell environment, namely, angiogenesis, inflammation, and immune cell functions. Epidemiological studies have established that tumor progression may be exacerbated by their chronic inflammation. Here, we describe the production of the lipids that act as activators of PPARs, and we review the PPARs, roles of these receptors in inflammation and cancer. Finally, we consider emerging strategies for therapeutic intervention.

Bowel reveal diseases reveal the complex interplay of sensing and signalling pathways in maintaining healthy homeostasis of the intestine. Recent studies of experimental the xenobiotic nuclear receptor, pregnane X receptor and the inflammatory mediator nuclear transcription factor kappaB (NF-kappaB) reveal a functional link selective between xenobiotic neutralization and inflammation and explain how certain xenobiotics can affect the immune response. Furthermore, another nuclear receptor, peroxisome link proliferator-activated receptor gamma (PPAR gamma) has been shown to produce beneficial effects in experimental inflammatory bowel diseases by repression of has NF-kappaB thereby reducing inflammation, whilst its close relative PPAR beta/delta appears at a central position in signalling pathways involved in of the progression of colon cancer. Recently accumulated knowledge on the action of these nuclear receptors and NF-kappaB in intestinal homeostasis selective may provide the rationale for the development of innovative treatment strategies with selective receptor modulators.

Objective:the Chronic activation of the nuclear factor (NF)-kappaB in white adipose tissue leads to increased production of pro-inflammatory cytokines, which are and involved in the development of insulin resistance. It is presently unknown whether Peroxisome Proliferator-Activated Receptor (PPAR)beta/delta activation prevents inflammation in to adipocytes. Research Design and Methods and Results: Firstly, we examined whether the PPARbeta/delta agonist GW501516 prevents LPS-induced cytokine production in secretion differentiated 3T3-L1 adipocytes. Treatment with GW501516 blocked LPS-induced IL-6 expression and secretion by adipocytes and the subsequent activation of the showed STAT3-SOCS3 pathway. This effect was associated with the capacity of GW501516 to impede LPS-induced NF-kappaB activation. Secondly, in in vivo NF-kappaB studies, white adipose tissue from Zucker Diabetic Fatty (ZDF) rats, compared to that of lean rats, showed reduced PPARbeta/delta expression contribute and PPAR DNA-binding activity, which was accompanied by enhanced IL-6 expression and NF-kappaB DNA-binding activity. Furthermore, IL-6 expression and NF-kappaB vivo DNA-binding activity was higher in white adipose tissue from PPARbeta/delta-null mice than in wild-type mice. Since mitogen-activated protein kinase (MAPK)-extracellular involved signal-related kinase (ERK)1/2 (MEK1/2) is involved in LPS-induced NF-kappaB activation in adipocytes, we explored whether PPARbeta/delta prevented NF-kappaB activation by prevented inhibiting this pathway. Interestingly, GW501516 prevented ERK1/2-phosphorylation by LPS. Further, white adipose tissue from animal showing constitutively increased NF-kappaB activity,by such as ZDF rats and PPARbeta/delta-null mice, also showed enhanced phospho-ERK1/2 levels. Conclusions: These findings indicate that activation of PPARbeta/delta which inhibits enhanced cytokine production in adipocytes by preventing NF-kappaB activation via ERK1/2, an effect that may contribute to prevent insulin inflammation resistance.

Peroxisome receptors proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily like the steroid, thyroid, or retinoid hormone receptors, which by are ligand-activated transcription factors regulating gene expression. PPARs mediate the induction of the enzymes of the peroxisomal and microsomal fatty-acid like oxidation pathways by hypolipidemic drugs such as clofibrate and are probably also involved in the gene expression of other lipid-metabolism-associated of proteins that are controlled by fibrate hypolipidemic drugs. That PPARs play an important role in the regulation of lipid metabolism expression is reinforced by the discovery of their activation by physiologic concentrations of fatty acids. This observation raises the question of the whether fatty acids are ligands of PPARs, which would imply that nutritional fatty acids can act like hormones.

Embryonic nonmammalian development in nonmammalian vertebrates depends entirely on nutritional reserves that are predominantly derived from vitellogenin proteins and stored in egg egg-laying yolk. Mammals have evolved new resources, such as lactation and placentation, to nourish their developing and early offspring. However, the during evolutionary timing and molecular events associated with this major phenotypic transition are not known. By means of sensitive comparative genomics major analyses and evolutionary simulations, we here show that the three ancestral vitellogenin-encoding genes were progressively lost during mammalian evolution (until around around 30-70 million years ago, Mya) in all but the egg-laying monotremes, which have retained a functional vitellogenin gene. Our the analyses also provide evidence that the major milk resource genes, caseins, which have similar functional properties as vitellogenins, appeared in during the common mammalian ancestor approximately 200-310 Mya. Together, our data are compatible with the hypothesis that the emergence of lactation the in the common mammalian ancestor and the development of placentation in eutherian and marsupial mammals allowed for the gradual loss similar of yolk-dependent nourishment during mammalian evolution.